After the exhaustive analysis of Synta Pharmaceuticals, it’s time to make the call to buy the stock or put it on the watch list (I haven’t seen any real red flags that would lead me to throw it out completely).
My biggest concern is with their cash flow. Even with the cash from […]
Filed under: Synta Pharmaceuticals (SNTA) | 6 Comments »
The only way to figure out the future value of a biotech company is to figure out how much they might make off of their drugs in clinical trials if they get approved by the FDA. Today, I’ll take a look at the markets for two of Synta’s potential drugs: STA-4784 and Apilimod. […]
Filed under: Synta Pharmaceuticals (SNTA) | Comment on this post »
Welcome to the March 27th version of the Carnival of Biotechnology. Thanks to Yali for letting me guest host the carnival. If you’d like to enter a post for a later edition or maybe even guest host, see the Carnival of Biotechnology submission and host information page.
Editor’s Picks
These weren’t submitted to the carnival, […]
Filed under: Blog Carnivals and Other Links | 8 Comments »
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 5 posts in the Synta Pharmaceuticals stock evaluation category.
As I’ve said before, I’m a scientist, not a business major, so feel free to point out in the comments any errors in thinking you find. I guess that goes […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 4 posts in the Synta Pharmaceuticals stock evaluation category.
Synta is a fairly small biotech company. As of the middle of January, they had 141 full time employees, 108 of which were engaged in research and development. Over half […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 3 posts in the Synta Pharmaceuticals stock evaluation category.
I won’t cover the rest of Synta’s drugs in too much detail since they are all relatively early in the pipeline, but here’s a synopsis on each:
STA-9090
STA-9090 is an inhibitor of […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 2 posts in the Synta Pharmaceuticals stock evaluation category.
Chronic Inflammatory Diseases
IL-12 and a related protein, IL-23, are cytokines (signaling protein that gets transfered from one cell to another) which stimulates T-cells in the the immune system. T-cells […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
I’ve read quite a few interesting posts about clinical trials in the last few days and I thought I’d share them with you.
Eye on FDA has a good post about FDA approval letters. Mark points out that companies have all the say on how much of the content of the letter gets released and highlights […]
Filed under: Evaluating Clinical Trials | 1 Comment »
In my last post, I mentioned that Synta had shown a doubling of progression-free survival in their STA-4783 phase 2b trial on melanomas. I thought I’d take a break from analyzing Synta and figure out if progression-free survival is really the best endpoint for them to be using (and is a doubling really […]
Filed under: Evaluating Clinical Trials | 1 Comment »
This is part two of the Investment report for Synta Pharmaceuticals.
Melanomas
Synta’s main drug is called STA-4783 which treats melanomas. Melanomas (skin cancer) affect 1 in almost 60 adults in the US in their lifetime. It affects over 60,000 people in the US every year and causes approximately 8,000 deaths. Since melanomas are on […]
Filed under: Synta Pharmaceuticals (SNTA) | 6 Comments »